Research Article


2019, 12(12): 2925–2932


Cyclodextrin conjugated ferritin nanocages reduce intracellular cholesterol level in foam cells

Samyukta Ravishankar1 and Sierin Lim1,2 (*)

View Author's information

1 School of Chemical and Biomedical Engineering, Nanyang Technological University, 70 Nanyang Drive, Blk N1.3, Singapore 637457, Singapore
2 NTU-Northwestern Institute for Nanomedicine, Nanyang Technological University, 50 Nanyang Drive, Blk N3.1, Singapore 637553, Singapore

Keywords: cyclodextrin, ferritin, protein nanocages, cholesterol sequestration, foam cells
Full article PDF
Cite this article(Endnote)
Share this article

views: 235

Citations: 0

  • Abstract
  • References
  • Electronic Supplementary Material
Accumulation of lipid-laden macrophages (foam cells) is characteristic of atherosclerosis development in the arterial walls. Ferritin nanocages have been found to passively accumulate in the atherosclerotic plaque. Ferritin has been actively investigated as a carrier for contrast agents in atherosclerosis diagnosis. We demonstrate the potential of ferritin as a carrier for therapeutic molecules to mediate cholesterol reduction from foam cells. Cyclodextrin molecules are chemically conjugated to the ferritin nanocages surface or encapsulated within the nanocages using metal co-loading methods. The cyclodextrin-conjugated ferritin has nanomolar affinity to cholesterol molecules. Treatment of foam cells with the conjugates shows decreased levels of intracellular accumulated cholesterol. The preferential localization of ferritin to foam cells is due to transferrin receptor-mediated endocytosis process. These findings show that ferritin nanocages as carriers localize cyclodextrin molecules to foam cells which mediate intracellular cholesterol reduction, thus highlighting its potential use as a therapeutic agent.
Related Article
Cite this article

Cyclodextrin conjugated ferritin nanocages reduce intracellular cholesterol level in foam cells. Nano Res. 2019, 12(12): 2925–2932

Download citation